Get Ahead with IPO Insights, IPO Prophet

IPO Prophet

Get Ahead with IPO Insights

At IPO Prophet®, our team leverages over three decades of expertise to deliver actionable quantitative analytics for the IPO market in real-time. This platform synthesizes our extensive experience investing in IPOs, providing investors with revolutionary tools to navigate the complexities of issuance day. Our mission is to empower investors with data-driven insights to make more informed decisions.

Equity Capital Markets

<ul><li>TRex Bio (TRXB) is preparing to offer 8,333,334 shares on the Nasdaq Global Select Market at $14–$16 per share .</li><li>At the $15 midpoint , the offering would raise approximately $125 million before expenses and value the company at approximately $411.7 million , based on 27.45 million shares outstanding after the offering , excluding the underwriters’ option.</li><li>J.P. Morgan, Evercore ISI, Cantor, Stifel and Wedbush PacGrow are underwriting the transaction. </li></ul>

TRex Bio (TRXB) is preparing to offer 8,333,334 shares on the Nasdaq Global Select Market at $14–$16 per share .At the $15 midpoint , the offering would raise approximately $125 million before expenses and value the company at approximately $411.7 million , based on 27.45 million shares outstanding after the offering , excluding the underwriters’ option.J.P. Morgan, Evercore ISI, Cantor, Stifel and Wedbush PacGrow are underwriting the transaction. 

TRex Bio (TRXB) Eyes $125 Million IPO to Advance Immune-Restoring Therapies

US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

<ul>
<li>Biotech remains the IPO market’s lone bright spot, with TRex Bio testing investor appetite as broader September IPOs struggled and Oura postponed. </li>
<li>TRex Bio is seeking $117–$133 million at a $384–$439 million valuation, backed by a Phase 1 lead program and a Lilly collaboration. </li>
<li>Lilly provides a significant validation signal, with a 23.9% pre-IPO stake and TRex Bio eligible for up to $577.5 million in additional milestones plus royalties.</li>
</ul>


Biotech remains the IPO market’s lone bright spot, with TRex Bio testing investor appetite as broader September IPOs struggled and Oura postponed. 
TRex Bio is seeking $117–$133 million at a $384–$439 million valuation, backed by a Phase 1 lead program and a Lilly collaboration. 
Lilly provides a significant validation signal, with a 23.9% pre-IPO stake and TRex Bio eligible for up to $577.5 million in additional milestones plus royalties.


TRex Bio (TRXB): Biotech Sector Remains Open as Lilly Backed Bio Sets Terms for IPO

United States

A clinical-stage biopharmaceutical company building on regulatory T cell (Treg) biology

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

TRex Bio (TRXB US)

TRex Bio (TRXB) Eyes $125 Million IPO to Advance Immune-Restoring Therapies

TRex Bio (TRXB) is preparing to offer 8,333,334 shares on the Nasdaq Global Select Market at $14–$16 per share . At the $15 midpoint , the...

IPO Prophet

TRex Bio (TRXB): Biotech Sector Remains Open as Lilly Backed Bio Sets Terms for IPO

TRex Bio brings a Treg-focused biotech platform to market with a Phase 1 lead asset, strong existing investors and Eli Lilly backing as biotech...

IPO Boutique

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)